Resources

Our online catalog indexes publications, presentations, and related resources for peers in our field.

Use the search and filter options below to find the resources you're looking for.

Related articles

Read our latest

2288 Resource s
2288 Resource s
    Date
    From
    To
  1. Journal article published in Medical Devices: Evidence and Research and co-authored by PATH's Alec Wollen and Patricia Coffey.
    Published: November 2022
    Resource Page
    Journal Article
  2. Journal article published in Global Health, Science and Practice and co-authored by PATH's Tran Thi Thu Ha and Nguyen Tuan Truong.
    Published: November 2022
    Resource Page
    Journal Article
  3. Journal article published in Clinical Infectious Diseases co-authored by PATH's Clint Pecenka, Melissa Malhame, and Philipp Lambach.
    Published: November 2022
    Resource Page
    Journal Article
  4. Acute Encephalitis Syndrome (AES) is a major public health concern in India, particularly in Uttar Pradesh (UP), where recurrent AES outbreaks have occurred since 1978. UP is the most populous state with an overburdened health system, and the incidence of AES is 9 cases per million population (2019) and a 5.8% mortality rate. Since 2019, there has been a steady decline in deaths due to AES in UP due to the implementation of series of system strengthening measures and a strong surveillance system.Timely intervention is a key component in reducing the case burden of AES which requires an integrated response system in the public healthcare infrastructure. This brief talks about the learnings from the project implemented by PATH in 75 districts of UP to ensure the retention of the improved system of reduced response time, supple surveillance system, efficient management, and improved capacity of healthcare providers.
    Published: November 2022
    Resource Page
    Brief
  5. Shigella is the leading bacterial cause of childhood diarrhea, and infections can have long-term effects on growth and development. No licensed Shigella vaccines currently exist, but several promising candidates in development could become available in a few years. PATH conducted a series of studies to better understand the public health value of potential Shigella vaccines and help inform decisions by international agencies, funders, vaccine developers, and national policymakers. As part of this work, PATH supported the development of two vaccine impact models to estimate the effects of reducing not only Shigella diarrhea but also Shigella-attributable stunting. One model measures cost-effectiveness based on health outcomes, and the other measures the long-term societal economic benefit of reducing stunting, focusing on its impact on future wages and productivity. This fact sheet provides an overview of the results.
    Published: November 2022
    Resource Page
    Fact Sheet